Evidence map›Paper›PMID 39432777›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

WDR20 prevents hepatocellular carcinoma senescence by orchestrating the simultaneous USP12/46-mediated deubiquitination of c-Myc.

Li Jiang, Xuxin Qi, Minshan Lai, Jiahao Zhou, Meng Yuan, Jieqiong You, Qiang Liu, Jinchang Pan, Luyao Zhao, Meidan Ying and 7 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Molecular and clinical oncology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Deubiquitylating Enzymes in Hepatocellular Carcinoma.International journal of biological sciences · 2025
    Review
  12. Article
  13. Organoids and spheroids: advancedFrontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Li Jiang *Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0003-4890-1206
Xuxin Qi *Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Minshan LaiZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Jiahao ZhouZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.ORCID 0009-0005-3621-6238
Meng YuanZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Jieqiong YouZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Qiang LiuAffiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China.
Jinchang PanLife Sciences Institute, Zhejiang University, Hangzhou 310058, China.
Luyao ZhaoKey Laboratory of Biotechnology of Antibiotic of National Health Commission, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Meidan YingZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Junfang JiCancer Center, Zhejiang University, Hangzhou 310058, China.
Ke LiKey Laboratory of Biotechnology of Antibiotic of National Health Commission, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Yan ZhangDepartment of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310016, China.ORCID 0000-0003-2189-0244
Weiwei PanDepartment of Cell Biology, College of Medicine, Jiaxing University, Jiaxing 314001, China.ORCID 0000-0002-3574-3758
Qiaojun HeZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Bo YangZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.
Ji CaoZhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0003-2813-6404

Funding

National Key R&D Program of China 2021YFA1300604the Fundamental Research Funds for the Central Universities 226-2023-00059Youth Fund of the National Natural Science Foundation of China 82304514Zhejiang Provincial Natural Science Foundation of China LQ23H310004
6 · The paper itself

Abstract

The dysfunction of the ubiquitin-proteasome system (UPS) facilitates the malignant progression of hepatocellular carcinoma (HCC). While targeting the UPS for HCC therapy has been proposed, identifying effective targets has been challenging. In this study, we conducted a focused screen of siRNA libraries targeting UPS-related WD40 repeat (WDR) proteins and found that silencing WDR20, a deubiquitinating enzyme activating factor, selectively inhibited the proliferation of HCC cells without affecting normal hepatocytes. Moreover, the downregulation of WDR20 expression induced HCC cellular senescence and suppressed tumor progression in xenograft, sleeping beauty transposon/transposase, and hydrodynamic tail vein injection-induced HCC models, and

Indexed as

Carcinoma, HepatocellularCellular SenescenceLiver NeoplasmsProto-Oncogene Proteins c-mycUbiquitinationUbiquitin ThiolesteraseAnimalsCarrier ProteinsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, TransgenicCarrier ProteinsMYC protein, humanProto-Oncogene Proteins c-mycUbiquitin ThiolesteraseWDR20 protein, humancellular senescencec-Mychepatocellular carcinomaUSP12/46WDR20

Identifiers

PMID39432777
PMCPMC11536108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.